JOURNAL OF DIGESTIVE DISEASES, cilt.16, sa.5, ss.286-292, 2015 (SCI-Expanded)
ObjectiveLow baseline viremia and an early treatment response predict the best outcomes in hepatitis B virus (HBV)-infected patients treated with nucleoside analogues with low barriers to resistance. The aim of this study was to assess the long-term results and effectiveness of lamivudine in patients with low baseline viremia and early virological treatment response.